Sanofi SA
featured
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
» Read More
.160x105.jpg?v=1366904651 "Fed Could Give Market a Safety Net")
More
-
Jan 31- Pfizer Inc's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook. Zoetis' over $2 billion public offering is the largest from a U.S. company since Facebook raised $16 billion last May.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said the drugmaker faced a tough year, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continued to erode business.
-
*Q4 sales $7.28 billion vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss warned on Thursday the drugmaker faced a tough year in 2013, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continue to erode business.
-
*Drug from Sanofi and Isis Pharmaceuticals to be sold as Kynamro. *FDA requiring four post-marketing studies. Jan 29- The U.S. Food and Drug Administration on Tuesday approved a drug made by Sanofi SA and Isis Pharmaceuticals Inc designed to treat a rare genetic disorder that causes dangerously high levels of bad LDL cholesterol.
-
*Drug from Sanofi and Isis Pharmaceuticals to be sold as Kynamro. *FDA requiring four post-marketing studies. Jan 29- The U.S. Food and Drug Administration on Tuesday approved a drug made by Sanofi SA and Isis Pharmaceuticals Inc designed to treat a rare genetic disorder that causes dangerously high levels of bad LDL cholesterol.
-
*Safeway, Rite Aid ship additional vaccine to U.S. stores. The Swiss drugmaker said the U.S. Food and Drug Administration will allow it to sell Tamiflu capsules in different packaging from what is currently available in the United States. Shortages of the treatment come as the United States is experiencing one of the worst influenza epidemics of the past decade.
-
GENEVA, Jan 16- Dengue is the world's fastest-spreading tropical disease and represents a "pandemic threat", infecting an estimated 50 million people across all continents, the World Health Organization said on Wednesday.
-
LONDON/ NEW YORK, Jan 15- Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12 months.
-
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
-
Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.
-
Widespread influenza activity has afflicted 47 states, according to the CDC. Phil Hosbach, VP of Immunization Policy, discusses whether people should be worried about dwindling supplies.
-
*Sanofi runs out of most vaccine dosages. Sanofi SA, the largest flu vaccine provider in the United States, said on Thursday it had sold out of four of the six different dosages of Fluzone seasonal flu vaccine due to unanticipated demand.
-
Ambien is a Sanofi drug, while Zolpimist, an oral spray, is made by NovaDel Pharma Inc. Edluar is manufactured by Swedish drugmaker Meda AB. However, the FDA did not recommend any change for a similar low-dose zolpidem product- Transcept Pharmaceuticals' Intermezzo- as the drug's label already recommends a lower dosage for women than for men.
-
Roche Holding AG told Reuters late on Wednesday that it had a shortage of the liquid formulation of Tamiflu, which is used mainly to slow down or stop the symptoms of the flu in children already infected with the virus.
-
Jan 10- This year's early and potentially severe flu season has created shortages of the children's formulation of the leading treatment and most forms of the top-selling flu vaccine in the United States, according to their manufacturers.
-
SAN FRANCISCO Jan 8- BioMarin Pharmaceutical Inc, which makes high-priced drugs used to treat rare diseases, would not consider a buy-out offer for even a 25-30 percent premium, according to the company's chief executive officer.
-
SAN FRANCISCO Jan 8- BioMarin Pharmaceutical Inc, which makes high-priced drugs used to treat rare diseases, has been approached by potential acquirers but would not sell itself for even a 25-30 percent premium, according to the company's chief executive officer.
-
Chris Viehbacher, CEO of Sanofi, discusses growing concern over the spread of the flu this season.
-
Jan 3- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. Forecast 2012 sales: $1.1 billion. Forecast 2012 sales: $830 million.